Clarity Pharmaceuticals (ASX:CU6) said results from a phase 2 diagnostic imaging study in patients with known or suspected neuroendocrine tumors showed that lesion detection by copper-64-Sartate outperformed Gallium-68-Dotatate, according to a Thursday Australian bourse filing.
The trial assessed the performance of the firm's Sartate imaging product as a potential new method to diagnose and manage neuroendocrine tumors.
Copper-64-Sartate detected 393 to 488 lesions, while Gallium-68-Dotatate identified 186 to 265 lesions.
Out of all the lesions identified, 230 to 251 of them were deemed to be discordant between copper-64-Sartate and Gallium-68-Dotatate scans, with nearly 94% of these discordant lesions detected only on the copper-64-Sartate scans.
Copper-64-Sartate was deemed safe and well tolerated, the filing said. The firm will start the next steps to conduct a registrational phase three study of copper-64-Sartate in neuroendocrine tumors with the US Food and Drug Administration's guidance.
The company recruited 45 participants with gastroenteropancreatic neuroendocrine tumors across four sites in Australia, comparing the diagnostic performance of copper-64-Sartate positron emission tomography (PET) at an average of four hours and around 20 hours post-administration to Gallium-68-Dotatate PET.
The firm's shares rose nearly 3% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。